GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced today that the Tech Council of Maryland (TCM) has named GlycoMimetics the winner of its 2012 Life Sciences Company of the Year award.

“To be recognized as the Life Sciences Firm of the Year by the Tech Council of Maryland is a tremendous honor to everyone at GlycoMimetics,” said Chief Executive Officer Rachel K. King. “Our immediate goal is to advance our lead drug candidate, GMI-1070, which is in a Phase 2 clinical trial in patients experiencing sickle cell crisis. We are hopeful that this drug can make a difference in treating this important medical need for an underserved patient population.”

The Tech Council of Maryland’s Tech Awards Celebration is regarded as Maryland’s premier awards ceremony for the technology community. TCM recognizes Mid-Atlantic companies in six categories: Life Sciences Firm of the Year, Executive of the Year, CFO of the Year, High Tech Firm of the Year, Government Contracting Firm of the Year, and Emerging Firm of the Year, the category in which GlycoMimetics was honored as a finalist in 2011. Each of this year’s winners has demonstrated a proven ability to grow, adapt and thrive in today’s business climate.

About the Tech Council of MD

The Tech Council of Maryland (TCM) is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland. TCM’s mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed. For more information, visit www.techcouncilmd.com.

About GlycoMimetics, Inc.

GlycoMimetics is a privately held biotechnology company that capitalizes on advances in the field of glycobiology. The company uses a specialized chemistry platform to rationally design new drug candidates. The company's initial focus is on therapeutics to treat inflammation, cancer, and infectious diseases. In October 2011, GlycoMimetics entered into an exclusive worldwide licensing agreement with Pfizer Inc. for the GlycoMimetics investigational compound GMI-1070. GMI-1070 is a pan-selectin antagonist currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease. GMI-1070 has received Orphan Drug and Fast Track status from the U.S. Food and Drug Administration (FDA). For additional information, please visit the company's web site: http://www.glycomimetics.com.